leisure time -WSS

leisure time

author：hotspot 2025-08-12 09:09:38 - browse：59982

Beam Therapeutics said Thursday morning it would lay off 20% of its staff — or around 100 employees — and pause or reevaluate certain programs as it looks to cut costs.

It’s a notable setback for a gene-editing company that quickly raised over $1 billion in the few years after its co-founder, David Liu, described a new form of CRISPR, called base editing, that allowed researchers to change individual letters of DNA. The biotech hired rapidly, announced its intention to treat a broad range of diseases, and received clearance to start clinical trials in cancer and sickle cell.

Beam, however, has struggled to enroll patients in those trials. Meanwhile, the biotech stock market has stayed cold, including for gene-editing companies, whose technologies raise new regulatory, safety, and reimbursement questions. The pending approval of two gene therapies for sickle cell would also limit the market for Beam’s lead drug.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Peter Hotez and the public health issue of online harassment

focus

WSS

It's time to get medical device identifiers over the finish line

California’s proposed $25 per hour health care minimum wage

Leqembi, other new Alzheimer’s drugs require better biomarkers

How the political right came to back psychedelics to treat trauma

Leqembi, other new Alzheimer’s drugs require better biomarkers

Virginia high school admissions case could be legal follow

focus

leisure time

Wikipedia

Medical records are filled with copy

Living with Fabry disease, a condition that causes chronic pain

Sports medicine is finally prioritizing gender equality

Oak trusses raised to roof of fire

In age of alternative facts, a scholarly course on calling out crap

Study: Pain burden is higher in Black NFL players than white ones

Guidelines to prevent youth baseball injuries need more muscle

Jerome Adams on the need for new antivirals for Covid

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Lecanemab for Alzheimer's is coming. Is the health system ready?

focus

Charles Manson follower Leslie Van Houten released from prison after 53 years

Peter Hotez and the public health issue of online harassment

A new study sees potential in DNA sequencing of infants

Elizabeth Holmes on track for early release from her 11

Retired US general questions alleged Putin, Prigozhin meeting

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

knowledge

focus

focus

hotspot